SHERIDAN, WYOMING – April 12, 2026 – The European Medicines Agency has launched its first-ever social media campaign in partnership with content creators, deploying the hashtag #HealthNotHype to push verified information about GLP-1 receptor agonists directly into the platforms where misinformation about these medicines is most prevalent. The month-long campaign targets Instagram — chosen specifically because of the high volume of GLP-1 conversations circulating there — and recruits creators from seven EU member states who are predominantly healthcare professionals or nutrition experts. With obesity and diabetes rates climbing globally, and celebrity endorsements driving a surge of public interest in GLP-1 drugs well beyond clinical circles, the EMA is betting that credible voices embedded in social media feeds can counterbalance the spread of counterfeit products and dangerous misuse.
What GLP-1 medicines actually are
GLP-1 receptor agonists were originally developed to treat type-2 diabetes. A subset of these medicines has since received regulatory approval for weight management in people living with obesity and weight-related health conditions — a distinction the EMA campaign is keen to reinforce. These are not over-the-counter supplements or quick-fix solutions; they are prescription medicines with specific indications, benefit-risk profiles, and contraindications that differ from patient to patient.
EMA Executive Director Emer Cooke spelled out the core message directly: GLP-1 receptor agonists are not magic solutions for weight loss. They carry both benefits and risks, are not appropriate for everyone, and function as long-term treatments that must run alongside lifestyle changes and remain under continuous medical supervision. The campaign exists precisely because that nuance is being lost in celebrity-driven social media discourse.
How the campaign is structured
Content creators were selected with deliberate care. The EMA vetted candidates across seven EU member states to ensure balanced geographical representation, and prioritised individuals whose communication track records reflect evidence-based information, transparency, and independence — the same standards the agency applies to its own outputs. Most of the participating creators are healthcare professionals or recognised experts in nutrition, giving the campaign scientific credibility rather than the influencer-marketing optics it could otherwise attract.
The primary channel is Instagram, where GLP-1 content — ranging from legitimate patient testimonials to dangerous anecdotal advice — already circulates at scale. Over the approximately one-month campaign window, creators will publish audiovisual content on their own channels and engage followers through interactive formats including quizzes and polls. This interactive element is deliberate: passive posts are easy to scroll past, while quizzes prompt users to test and question what they already believe about these medicines.
The misinformation and counterfeit risk
Part of what the EMA is responding to is a documented pattern: as demand for GLP-1 medicines rises, so does the illegal market for counterfeit versions. News coverage, social media trends, and high-profile celebrity endorsements have pushed public awareness far beyond what healthcare systems were designed to accommodate, creating conditions where patients seek out unregulated products or self-administer without supervision. The risks in that scenario extend beyond inefficacy — counterfeit injectable medicines carry serious safety hazards.
The #HealthNotHype campaign is an attempt to insert regulated, validated information into the same channels feeding that demand. By choosing creators who already have established followings in health communication, the EMA is trying to reach audiences who may never seek out an agency press release but regularly consume health content through their social feeds.
Why it matters
For patients currently using or considering GLP-1 medicines, the campaign has direct practical consequences. Misinformation about dosing, eligibility, and the need for medical supervision can lead individuals to self-medicate, use counterfeit products, or abandon the lifestyle changes that clinical guidelines say must accompany these treatments. Clearer public messaging reduces those risks and sets more realistic expectations about what the medicines can and cannot do.
For healthcare professionals across the EU, the campaign addresses a pressure point many clinics are already feeling: patients arriving with social-media-shaped expectations that do not match their clinical profile. When the general public holds more accurate baseline knowledge about GLP-1 indications and risks, consultations become more productive and the burden of correcting misinformation in the clinic decreases. Regulators beyond the EU are also watching — the EMA's move to work directly with credentialed content creators on a controlled, values-aligned campaign may serve as a replicable model for public health communication in an era when social platforms routinely outpace official channels in reach and speed.